Nrg-Gy005-A Randomized Phase II/III Study Of The Combination Of Cediranib And Olaparib Compared To Cediranib Or Olaparib Alone, Or Standard Of Care Chemotherapy In Women With Recurrent Platinum-Resistant Or -Refractory Ovarian, Fallopian Tube, Or Primary
Posted Date: Oct 1, 2019
- Investigator: Thomas Herzog
- Specialties: Cancer, Gynecologic Oncology, Gynecology, Oncology, Ovarian Cancer
- Type of Study: Drug
The goal of this study is To assess the efficacy and identify (in)active arm(s) of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by PFS in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer.
Criteria:
To Be Eligible: Diagnosed With Ovarian, Peritoneal, Or Fallopian Tube Cancer, Controlled Blood Pressure, >18 Years Of Age, No Prior Use Of Parp Inhibitors, No Uncontrolled Or Active Illness, Nonpregnant/Nonbreastfeeding
Keywords:
Ovarian Cancer, Peritoneal, Gynecology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com